ClinicalTrials.gg
Not yet recruitingNCT07051096RESPITEUpdated Jul 3, 2025

Responsive Nature-Driven Imagery to Reduce Delirium After Cardiac Surgery

An interventional study of A novel device developed providing nature-driven responsive imagery that responds to the patient's physiological to distract, engage, and de-escalate behaviours of delirium. and Routine post-operative management and standard delirium reduction measures. in Delirium - Postoperative, Agitation and Anxiety, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by University of British Columbia · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Emergence Delirium with a site in Canada — 5 open to participants now, 6 under way, none of them phase 3. Emergence Delirium · Canada.

Planned enrollment
10th of 12
60 · median 199
Started
2025
with 1 other
No phase
9 of 16
2 open now
Registered
15th of 16
by date
Lead sponsor
3 of 16
University of British Columbia

Among the 16 studies in Emergence Delirium with a site in Canada, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, and was the 15th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

5 of the 16 studies in Emergence Delirium with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Emergence Delirium with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a novel device (MindfulGarden) is beneficial in a population of patients undergoing cardiac surgery. The main questions it aims to answer are:

Is a novel device (MindfulGarden) that uses responsive nature-driven imagery feasible in patients undergoing cardiac surgery? Will use of this device reduce the use of psychotropic medications, improve recovery experience, and improve delirium?

Participants will receive routine post-operative management and standard delirium reduction measures. They will be randomized into two groups where one receives the novel device (MindfulGarden) and the other does not.

Read the detailed description

Hypotheses:

This study will explore: (1) the feasibility of using Mindful Garden-a novel, nature-based digital therapeutic device offering responsive imagery and sound with biofeedback-in patients undergoing cardiac surgery; and (2) whether its use reduces psychotropic medication use, agitation, anxiety, and both the incidence and duration of postoperative delirium.

Rationale:

Delirium is a frequent, serious complication after cardiac surgery, leading to prolonged hospital stays, increased costs, and higher mortality rates. Although medications are often used to manage delirium-related behavior, they can lead to over-sedation and do not reliably prevent or treat delirium. There is an urgent need for safe, effective, non-pharmacological interventions in high-risk groups. Mindful Garden offers a screen-based display of dynamic nature scenes with interactive elements that respond to physiological cues. In prior ICU settings, brief exposure to Mindful Garden reduced agitation and the need for unscheduled medications. However, its effectiveness in preventing or managing delirium specifically in cardiac surgical patients remains unexplored.

Objectives:

The primary goals are to evaluate the feasibility of implementing Mindful Garden (in terms of recruitment, adherence, data completeness), its usage patterns, and patient satisfaction. Secondary aims include assessing the device's impact on delirium incidence and severity, need for psychotropic medications, agitation levels, anxiety, postoperative recovery, and length of hospital stay.

Participants:

This pilot randomized controlled trial will enroll 60 adult patients (aged ≥18 years) undergoing open-heart surgery at St. Paul's Hospital in Vancouver, Canada. Each arm will include 30 patients. Participants must have at least one risk factor for delirium, including being aged 64 or older, a history of delirium, stroke or TIA, cognitive impairment, or depression. Individuals with severe pre-existing cognitive impairments will be excluded.

Intervention:

Participants will be randomized 1:1 to either the Mindful Garden intervention or standard care. Due to the nature of the intervention, blinding is not feasible. In the intervention group, the Mindful Garden device will be made available for up to 7 days postoperatively or until discharge. All participants will receive standard post-operative care, including routine non-drug delirium prevention measures.

Outcomes:

Primary feasibility outcomes include recruitment success, adherence to study protocol, and participant satisfaction. Secondary clinical outcomes involve:

  • Frequency of unscheduled psychotropic medication use
  • Incidence and severity of delirium (measured via the Intensive Care Delirium Screening Checklist and Confusion Assessment Method)
  • Agitation (Richmond Agitation Sedation Scale)
  • Anxiety (State Trait Anxiety Inventory)
  • Recovery quality (QoR-15 score)
  • Presence of Hallucinations (PSYRATS)
  • Hospital length of stay

Anticipated Impact:

This pilot trial will assess whether integrating the Mindful Garden device into post-cardiac surgery care is practical and beneficial. Results will inform a larger trial and may support broader implementation of non-pharmacological digital therapeutics to enhance recovery, reduce delirium, and minimize reliance on psychoactive drugs in surgical settings.

03

Conditions studied

  • Delirium - Postoperative
  • Agitation
  • Anxiety
  • Cardiac Surgery Recovery

Keywords

  • Randomized trial
  • Delirium
  • Cardiac surgery
  • MindfulGarden
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Planned open-heart cardiac surgery (e.g. coronary artery bypass grafting, valve replacement surgery);
  • Able to understand study procedures and provide in English;
  • At least one delirium risk factor: 1) Age less than 65yrs; 2) History of delirium; 3) History of stroke/; 4) Known cognitive impairment; 5) Depression requiring medication.

Exclusion criteria

Exclusion Criteria:

  • Severe pre-existing cognitive impairment ( [MOCA6]\<10)
  • Uncorrected visual impairment;
  • Significant impairment from psychiatric disease;
  • Enrolment in another clinical trial which may interfere with the study outcome measures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Receives the MindfulGarden intervention in addition to routine post-operative management and standard delirium reduction measures.

    Device: A novel device developed providing nature-driven responsive imagery that responds to the patient's physiological to distract, engage, and de-escalate behaviours of delirium.

  • Active comparator
    Control Group

    Participants will receive standard care, which includes routine post-operative care pathways for cardiac surgery, and standard delirium reduction measures.

    Procedure: Routine post-operative management and standard delirium reduction measures.

Interventions

  • DeviceA novel device developed providing nature-driven responsive imagery that responds to the patient's physiological to distract, engage, and de-escalate behaviours of delirium.

    This device will be provided on top of routine post-operative management and standard delirium reduction measures. It has proven effective in a previous clinical trial by reducing agitation and unscheduled medications. It displays nature-driven responsive imagery through an available mobile screen/device for the first 7 days after surgery or discharge, whichever comes first. The imagery adapts in real-time to the participant's movement and sound. The device will be placed at the foot of the bed while the patient is awake and may be interrupted at the discretion of the patient, bedside RN or attending physician.

    Also known as: MindfulGarden

  • ProcedureRoutine post-operative management and standard delirium reduction measures.

    Examples of routine post-operative care are sleep optimization, avoidance of delirium-promoting medications, orientation, and mobilization.

06

What researchers measure

Primary outcomes

  1. Recruitment Rate

    Time frame: Day 0

  2. Adherence to Protocol Rate

    Time frame: Day 30 post surgery

  3. Time Spent with Device

    Time frame: Day 7 post surgery or discharge, whichever comes first

  4. Patient Satisfaction and Perceived Benefits

    Using a Likert Scale in a patient satisfaction questionnaire. The Likert Scale uses 1 as Strongly Disagree and 5 as Strongly Agree.

    Time frame: Day 7 post surgery or discharge, whichever comes first

Secondary outcomes

  1. Incidence and Severity (days) of Delirium

    Measured by the Intensive Care Delirium Screening Checklist in the CSICU and the Confusion Assessment Method after discharge to the ward.

    Time frame: Twice daily until Day 7 post surgery or discharge, whichever comes first

  2. Number of Unscheduled Psychoactive Medications or IV Infusions

    Examples of medications are haloperidol, loxapine, and dexmedetomidine

    Time frame: Day 7 post surgery or discharge, whichever comes first

  3. Agitation in CSICU

    Measured using the Richmond Agitation Sedation Scale: Positive scores (+1 to +4): Indicate increasing agitation or restlessness. Negative scores (-1 to -5): Indicate increasing levels of sedation or unconsciousness. A score of 0: represents the desired state of alertness and calmness

    Time frame: Every 4 hours while admitted to CSICU

  4. Patient reported outcomes of anxiety

    Patient reported outcomes of anxiety will be measured using the State Trait Anxiety Inventory. The State Trait Anxiety Inventory consists of 40 items in total. 20 items for State Anxiety (S-Anxiety) range 20-80 and 20 items for Trait Anxiety (T-Anxiety) range 20-80.

    Time frame: Day 0, 3, 30 post surgery

  5. Length of CSICU and hospital stays (days)

    Time frame: Day 30 or day of discharge, whichever comes first

  6. Patient reported Quality of Recovery

    Measured using Quality of Recovery (QoR-15). Patients score items on a 1 to 5 scale with 1 being Not at All and 5 being Extremely. These scores are totalled where 15-30 indicates Poor Quality of Recovery, 31-50 indicates Moderate Quality of Recovery, and 51-75 indicates Good Quality of Recovery.

    Time frame: Day 0, 3, 30 post surgery

  7. Presence of hallucinations and delusions

    Measured using the Psychotic Symptom Rating Scales (PSYRATS). PSYRATS has 2 subscales: Auditory Hallucinations (AH) and Delusions (D). AH has 11 items each scored 0-4 with a sum of 0 indicating no symptoms and a sum of 44 indicating most severe symptoms. D has 6 items each scored 0-4 with a sum of 0 indicating no symptoms and a sum of 24 indicating most severe symptoms.

    Time frame: Day 3 post surgery

07

Study locations

1 site
08

References and documents

Publications

  • Nicholas M, Wittmann J, Norena M, Ornowska M, Reynolds S. A randomized, clinical trial investigating the use of a digital intervention to reduce delirium-associated agitation. NPJ Digit Med. 2023 Oct 30;6(1):202. doi: 10.1038/s41746-023-00950-4. PubMed 37903857 ↗
  • Tse L, Schwarz SK, Bowering JB, Moore RL, Barr AM. Incidence of and Risk Factors for Delirium After Cardiac Surgery at a Quaternary Care Center: A Retrospective Cohort Study. J Cardiothorac Vasc Anesth. 2015 Dec;29(6):1472-9. doi: 10.1053/j.jvca.2015.06.018. Epub 2015 Jun 12. PubMed 26395395 ↗

Individual participant data

Plan to share: No — Confidentiality restrictions from institution.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.

Of 186 non-industry interventional studies with no phase under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 15 months is below that.

Counting every sponsor, half of 186 studies reached it within 19 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Jul 3, 2025
StartEst.
Sep 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07051096
Collaborators
Canadian Anesthesiologists' Society
Responsible party
Alana Flexman (Clinical Associate Professor, University of British Columbia) — Principal investigator
First posted
Jul 3, 2025
Start date
Sep 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jul 3, 2025

Study contacts

Alana Flexman, MD
Contact
aflexman@providencehealth.bc.ca
604-682-2344 ext. 62115
Alana Flexman, MD MBA
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion